Treatment of long term Anemia
- Conditions
- Health Condition 1: D638- Anemia in other chronic diseases classified elsewhere
- Registration Number
- CTRI/2024/03/063692
- Lead Sponsor
- Sura. Amarendar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Painful crises (in the past 12 months, there were more than three occurrences)
More than two blood transfusions in the last 12 months. The term painful crisis refers to an acute painful occurrence that necessitates the use of oral or injectable analgesics and lasts for at least 4 hours when no other reason can be found to account for the symptom
Patients under hydroxyurea therapy will be approached to enrol in this study to assess splenic hypofunction
children under the age of 3years and adults over 60years of age
concomitant diseases such as neutropenia and thrombocytopenia may have increased the hydroxyureas toxicity
Patients who are participating in a particular program or study that could have had an impact on their clinical or haematological state
renal dysfunction is indicated by blood creatinine levels that are 1.5 time or more above normal
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anticipate a statistically significant increase in HbF levels in Sickle Cell Anemia patients following Hydroxyurea treatment.Timepoint: 4weeks
- Secondary Outcome Measures
Name Time Method Expect improvement in splenic function, as evidenced by imaging techniques, attributed to the reduction of sickle cell-related complications and improved overall hemoglobin profiles. <br/ ><br> <br/ ><br>Envisage a reduction in the frequency and severity of vaso-occlusive crises, leading to improved patient quality of life <br/ ><br>Timepoint: 1year